Marie-Christine Rio

Marie-Christine Rio

Auto-generated profile, based on publicly available information

Marie-Christine Rio

Department of Functional Genomics and Cancer, Institut de Génétique et Biologie Moléculaire et Cellulaire (IGBMC)/ CNRS UMR 7104/ INSERM U 964/ Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in The International Journal of Developmental Biology
Verified
Journal Article
Closed access
JTJinxiang Tan
Jinxiang Tan
EBEmilie Buache
Emilie Buache
MCMarie-Pierre Chenard
Marie-Pierre Chenard
NDNassim Dali-Youcef
Nassim Dali-Youcef
MRMarie-Christine Rio
Marie-Christine Rio
While the participation of adipocytes is well known in tissue architecture, energy supply and endocrine processes, their implication during natural cancer history is just beginning to unfold. An extensive review of the literature concerning the impact of resident adipocytes on breast cancer development/progression was performed. This review provides in vitro and in vivo evidence that adipocytes located close to invasive cancer cells, referred to as cancer-associated adipocytes (CAAs), are essential for breast tumor development/progression. Their deleterious function is dependent, at least partly, on their crosstalk with invasive cancer cells. Indeed, this event leads to dramatic phenotypic and/or functional modifications of both cell types. Adipocytes exhibit delipidation and acquire a fibroblast-like shape. In parallel, cancer cell aggressiveness is exacerbated through increased migratory and invasive properties. Moreover, obesity is currently a sign of poor prognosis in human carcinomas. In this context, a high number of "obese" resident adipocytes might be predicted to be detrimental. Accordingly, there are some similarities between the molecular alterations observed in hypertrophied adipocytes and in CAAs. How adipocytes function to favor tumorigenesis at the molecular level remains largely unknown. Nevertheless, progress has been made recently and molecular clues are starting to emerge. Deciphering the cellular and molecular mechanisms behind the adipocyte-cancer cell heterotypic crosstalk is of great interest since it might provide new targets for improving diagnosis/prognosis and for the design of innovative therapeutic strategies. They might also improve our understanding of the relationship between obesity/metabolic disorders and cancer risk and/or poor patient outcome.

28 February 2011 in Oncogene
Verified
Journal Article
Open access
EBE Buache
E Buache
NENicolas ETIQUE
Nicolas ETIQUE
FAFabien Alpy
Fabien Alpy
ISI Stoll
I Stoll
MMM Muckensturm
M Muckensturm
MRM C Rio
M C Rio
Although trefoil factor 1 (TFF1; previously named pS2) is abnormally expressed in about 50% of human breast tumors, its physiopathological role in this disease has been poorly studied. Moreover, controversial data have been reported. TFF1 function in the mammary gland therefore needs to be clarified. In this study, using retroviral vectors, we performed TFF1 gain- or loss-of-function experiments in four human mammary epithelial cell lines: normal immortalized TFF1-negative MCF10A, malignant TFF1-negative MDA-MB-231 and malignant TFF1-positive MCF7 and ZR75.1. The expression of TFF1 stimulated the migration and invasion in the four cell lines. Forced TFF1 expression in MCF10A, MDA-MB-231 and MCF7 cells did not modify anchorage-dependent or -independent cell proliferation. By contrast, TFF1 knockdown in MCF7 enhanced soft-agar colony formation. This increased oncogenic potential of MCF7 cells in the absence of TFF1 was confirmed in vivo in nude mice. Moreover, chemically induced tumorigenesis in TFF1-deficient (TFF1-KO) mice led to higher tumor incidence in the mammary gland and larger tumor size compared with wild-type mice. Similarly, tumor development was increased in the TFF1-KO ovary and lung. Collectively, our results clearly show that TFF1 does not exhibit oncogenic properties, but rather reduces tumor development. This beneficial function of TFF1 is in agreement with many clinical studies reporting a better outcome for patients with TFF1-positive breast primary tumors.

21 October 2013 in Oncogene
Verified
Journal Article
Open access
PDF file
JTJ Tan
J Tan
EBE Buache
E Buache
FAFabien Alpy
Fabien Alpy
EDE Daguenet
E Daguenet
Catherine TOMASETTOCatherine TOMASETTO
Catherine TOMASETTO
MRM-C Rio
M-C Rio
MMP-11 is a bad prognosis paracrine factor in invasive breast cancers. However, its mammary physiological function remains largely unknown. In the present study we have investigated MMP-11 function during postnatal mammary gland development and function using MMP-11-deficient (MMP-11−/−) mice. Histological and immunohistochemical analyses as well as whole-mount mammary gland staining show alteration of the mammary gland in the absence of MMP-11, where ductal tree, alveolar structures and milk production are reduced. Moreover, a series of transplantation experiments allowed us to demonstrate that MMP-11 exerts an essential local paracrine function that favors mammary gland branching and epithelial cell outgrowth and invasion through adjacent connective tissues. Indeed, MMP-11−/− cleared fat pads are not permissive for wild-type epithelium development, whereas MMP-11−/− epithelium transplants grow normally when implanted in wild-type cleared fat pads. In addition, using primary mammary epithelial organoids, we show in vitro that this MMP-11 pro-branching effect is not direct, suggesting that MMP-11 acts via production/release of stroma-associated soluble factor(s). Finally, the lack of MMP-11 leads to decreased periductal collagen content, suggesting that MMP-11 has a role in collagen homeostasis. Thus, local stromal MMP-11 might also regulate mammary epithelial cell behavior mechanically by promoting extracellular matrix stiffness. Collectively, the present data indicate that MMP-11 is a paracrine factor involved during postnatal mammary gland morphogenesis, and support the concept that the stroma strongly impact epithelial cell behavior. Interestingly, stromal MMP-11 has previously been reported to favor malignant epithelial cell survival and promote cancer aggressiveness. Thus, MMP-11 has a paracrine function during mammary gland development that might be harnessed to promote tumor progression, exposing a new link between development and malignancy.

17 February 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Sébastien BlaiseSébastien Blaise
Sébastien Blaise
MKMarie Kneib
Marie Kneib
ARAdrien Rousseau
Adrien Rousseau
FGFrederic Gambino
Frederic Gambino
MCMarie-Pierre Chenard
Marie-Pierre Chenard
MRMarie-Christine Rio
Marie-Christine Rio
Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) are major signal transducers for the TNF and interleukin-1/Toll-like receptor superfamilies. However, TRAF4 does not fit the paradigm of TRAF function in immune and inflammatory responses. Its physiological and molecular functions remain poorly understood. Behavorial analyses show that TRAF4-deficient mice (TRAF4-KO) exhibit altered locomotion coordination typical of ataxia. TRAF4-KO central nervous system (CNS) ultrastructure shows strong myelin perturbation including disorganized layers and disturbances in paranode organization. TRAF4 was previously reported to be expressed by CNS neurons. Using primary cell culture, we now show that TRAF4 is also expressed by oligodendrocytes, at all stages of their differentiation. Moreover, histology and electron microscopy show degeneration of a high number of Purkinje cells in TRAF4-KO mice, that was confirmed by increased expression of the Bax pro-apoptotic marker (immunofluorescence), TUNEL analysis, and caspase-3 activation and PARP1 cleavage (western blotting). Consistent with this phenotype, MAG and NogoA, two myelin-induced neurite outgrowth inhibitors, and their neuron partners, NgR and p75NTR were overexpressed (Q-RT-PCR and western blotting). The strong increased phosphorylation of Rock2, a RhoA downstream target, indicated that the NgR/p75NTR/RhoA signaling pathway, known to induce actin cytoskeleton rearrangement that favors axon regeneration inhibition and neuron apoptosis, is activated in the absence of TRAF4 (western blotting). Altogether, these results provide conclusive evidence for the pivotal contribution of TRAF4 to myelination and to cerebellar homeostasis, and link the loss of TRAF4 function to demyelinating or neurodegenerative diseases.

29 April 2016 in Scientific Reports
Verified
Journal Article
Open access
NDNassim Dali-Youcef
Nassim Dali-Youcef
KHKarim Hnia
Karim Hnia
Sébastien BlaiseSébastien Blaise
Sébastien Blaise
NMNadia Messaddeq
Nadia Messaddeq
SBStéphane Blanc
Stéphane Blanc
MRMarie-Christine Rio
Marie-Christine Rio
MMP11 overexpression is a bad prognostic factor in various human carcinomas. Interestingly, this proteinase is not expressed in malignant cells themselves but is secreted by adjacent non-malignant mesenchymal/stromal cells, such as cancer associated fibroblasts (CAFs) and adipocytes (CAAs), which favors cancer cell survival and progression. As MMP11 negatively regulates adipogenesis in vitro, we hypothesized that it may play a role in whole body metabolism and energy homeostasis. We used an in vivo gain- (Mmp11-Tg mice) and loss- (Mmp11−/− mice) of-function approach to address the systemic function of MMP11. Strikingly, MMP11 overexpression protects against type 2 diabetes while Mmp11−/− mice exhibit hallmarks of metabolic syndrome. Moreover, Mmp11-Tg mice were protected from diet-induced obesity and display mitochondrial dysfunction, due to oxidative stress, and metabolic switch from oxidative phosphorylation to aerobic glycolysis. This Warburg-like effect observed in adipose tissues might provide a rationale for the deleterious impact of CAA-secreted MMP11, favouring tumor progression. MMP11 overexpression also leads to increased circulating IGF1 levels and the activation of the IGF1/AKT/FOXO1 cascade, an important metabolic signalling pathway. Our data reveal a major role for MMP11 in controlling energy metabolism, and provide new clues for understanding the relationship between metabolism, cancer progression and patient outcome.

1 August 2014 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
EBEmilie Buache
Emilie Buache
RTRobert Thai
Robert Thai
CWCorinne Wendling
Corinne Wendling
FAFabien Alpy
Fabien Alpy
APAdeline Page
Adeline Page
MRMarie‐Christine Rio
Marie‐Christine Rio
MMP‐11 is a key factor in physiopathological tissue remodeling. As an active form is secreted, its activity must be tightly regulated to avoid detrimental effects. Although TIMP‐1 and TIMP‐2 reversibly inhibit MMP‐11, another more drastic scenario, presumably via hydrolysis, could be hypothesized. In this context, we have investigated the possible implication of MMP‐14, since it exhibits a spatiotemporal localization similar to MMP‐11. Using native HFL1‐produced MMP‐11 and HT‐1080‐produced MMP‐14 as well as recombinant proteins, we show that MMP‐11 is a MMP‐14 substrate. MMP‐14 cleaves MMP‐11 catalytic domain at the PGG(P1)‐I(P1′)LA and V/IQH(P1)‐L(P1′)YG scissile bonds, two new cleavage sites. Interestingly, a functional test showed a dramatical reduction in MMP‐11 enzymatic activity when incubated with active MMP‐14, whereas inactive point‐mutated MMP‐14 had no effect. This function is conserved between human and mouse. Thus, in addition to the canonical reversible TIMP‐dependent inhibitory system, irreversible MMP proteolytic inactivation might occur by cleavage of the catalytic domain in a MMP‐dependent manner. Since MMP‐14 is produced by HT‐1080 cancer cells, whereas MMP‐11 is secreted by HFL1 stromal cells, our findings support the emerging importance of tumor‐stroma interaction/cross‐talk. Moreover, they highlight a Janus‐faced MMP‐14 function in the MMP cascade, favoring activation of several pro‐MMPs, but limiting MMP‐11 activity. Finally, both MMPs are active at the cell periphery. Since MMP‐14 is present at the cell membrane, whereas MMP‐11 is soluble into the cellular microenvironment, this MMP‐14 function might represent one critical regulatory mechanism to control the extent of pericellular MMP‐11 bioavailability and protect cells from excessive/inappropriate MMP‐11 function.